CIG
REGN icon

CHB Investment Group’s Regeneron Pharmaceuticals REGN Stock Holding History

CHB Investment Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,597
Closed -$1.65M – 86
2025
Q1 		$1.65M Buy
2,597
+84
+3% +$57.8K 0.88% 53
2024
Q4 		$1.79M Buy
2,513
+10
+0.4% +$8.39K 0.97% 52
2024
Q3 		$2.63M Buy
+2,503
New +$2.79M 1.4% 36

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

CHB Investment Group's REGN Position: Q2 2025 in Review

CHB Investment Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 2,597 shares — an estimated $1.65M sold.

CHB Investment Group first reported a position in REGN in Q3 2024 and held it in 3 quarters. The position peaked at $2.63M in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • CHB Investment Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • CHB Investment Group sold 2,597 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $1.65M.
  • CHB Investment Group first reported a position in Regeneron Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • CHB Investment Group's Regeneron Pharmaceuticals position peaked at $2.63M in Q3 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on CHB Investment Group's 13F filing for Q2 2025, filed 15 Jul 2025.